Affimed Nv Stock Today
| AFMD Stock | USD 0.88 0.01 1.12% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Affimed NV is trading at 0.88 as of the 17th of March 2025, a 1.12 percent down since the beginning of the trading day. The stock's lowest day price was 0.85. Affimed NV has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of September 2014 | Category Healthcare | Classification Health Care |
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany. Affimed NV operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 16.39 M outstanding shares of which 702.39 K shares are presently shorted by private and institutional investors with about 7.47 trading days to cover. More on Affimed NV
Moving together with Affimed Stock
Moving against Affimed Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Affimed Stock Highlights
| CEO | Adi Hoess | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAffimed NV can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Affimed NV's financial leverage. It provides some insight into what part of Affimed NV's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Affimed NV (AFMD) is traded on NASDAQ Exchange in USA. It is located in Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165 and employs 76 people. Affimed NV is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.43 M. Affimed NV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 16.39 M outstanding shares of which 702.39 K shares are presently shorted by private and institutional investors with about 7.47 trading days to cover.
Affimed NV currently holds about 237.23 M in cash with (110.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Affimed NV Probability Of Bankruptcy
Ownership AllocationAffimed NV holds a total of 16.39 Million outstanding shares. Affimed NV shows 6.0 percent of its outstanding shares held by insiders and 23.82 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Affimed Ownership Details
Affimed Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 42.2 K | |
| Commonwealth Equity Services Inc | 2024-12-31 | 21.4 K | |
| Aberdeen Group Plc | 2024-12-31 | 20.9 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 18.1 K | |
| Clayton Financial Group Llc | 2024-12-31 | 15 K | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 10.1 K | |
| Rsm Us Wealth Management Llc | 2024-12-31 | 10 K | |
| Barclays Plc | 2024-12-31 | 7.5 K | |
| Wells Fargo & Co | 2024-12-31 | 7.2 K | |
| 683 Capital Management Llc | 2024-12-31 | 654.6 K | |
| Nea Management Company, Llc | 2024-12-31 | 442.6 K |
Affimed NV Historical Income Statement
Affimed Stock Against Markets
Affimed NV Corporate Management
| Uwe Reusch | Head Culture | Profile | |
| Denise Mueller | Chief Board | Profile | |
| RPh PharmD | Chief Officer | Profile | |
| Arndt MD | Chief Board | Profile | |
| Angus Smith | CFO Board | Profile | |
| Michael Wolf | Head Administration | Profile | |
| Andreas MD | Chief Board | Profile |
Already Invested in Affimed NV?
The danger of trading Affimed NV is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Affimed NV is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Affimed NV. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Affimed NV is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Affimed NV is a strong investment it is important to analyze Affimed NV's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Affimed NV's future performance. For an informed investment choice regarding Affimed Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Affimed NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Affimed Stock refer to our How to Trade Affimed Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Affimed NV. If investors know Affimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Affimed NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.95) | Revenue Per Share | Quarterly Revenue Growth (0.92) | Return On Assets | Return On Equity |
The market value of Affimed NV is measured differently than its book value, which is the value of Affimed that is recorded on the company's balance sheet. Investors also form their own opinion of Affimed NV's value that differs from its market value or its book value, called intrinsic value, which is Affimed NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Affimed NV's market value can be influenced by many factors that don't directly affect Affimed NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Affimed NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Affimed NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Affimed NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.